Virpax Pharmaceuticals, Inc. VRPX
0.01
0.00
0.00%
as of 24 Sep
- Market cap
- $160.0K
- P/E
- 0.0×
Follow VRPX
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.05 | 0.02 | 0.02 | 18.96 | 6.36 | 1.25 | 0.63 |
Net Debt/EBITDA |
— | (0.17) | 0.01 | (0.23) | 3.06 | 0.87 | 0.58 | 0.13 |
Debt/Assets |
0.00% | 813.01% | 0.00% | 219.51% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (0.42) | 0.00 | (0.24) | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.68 | 0.34 | 0.32 | 1.21 | 0.82 | 0.65 | 1.39 |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 134.57% | 168.48% | 124.91% | (72.48%) | (80.09%) | (164.09%) | (2,364.96%) | |
| — | (8,588.29%) | (6,111.83%) | (1,694.86%) | (60.22%) | (73.09%) | (103.68%) | (215.80%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (1,169.25%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 221.42% | 121.02% | 120.99% | (32.16%) | (130.59%) | (785.27%) | 1,320.55% |
Average Days of Receivables |
— | — | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.35) | (96.73) | (111.69) | (544.67) | (381.34) | (210.55) | (98.20) |
Cash per Share |
— | 0.01 | 3.55 | 4.42 | 1,379.85 | 405.88 | 195.33 | 8.89 |
Shareholders Equity per Share |
— | (0.23) | (233.53) | (340.01) | 1,403.93 | 354.25 | 41.33 | (5.37) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.23) | (233.53) | (340.01) | 1,403.93 | 354.25 | 41.33 | (5.37) |
Free Cash Flow |
— | (1.80) | (1.13) | (1.38) | (14.54) | (17.85) | (9.85) | (16.71) |
Working Capital |
— | (1.19) | (2.73) | (3.59) | 37.48 | 16.58 | 1.93 | (0.91) |
Net Current Asset Value |
— | (1.19) | (2.73) | (4.61) | 37.48 | 16.58 | 1.93 | (0.91) |
| Other line items | ||||||||
Quick Ratio |
— | 0.04 | 0.01 | 0.02 | 17.65 | 6.14 | 1.19 | 0.61 |
Cash ROIC |
— | 279.31% | 42.06% | 44.11% | (19.57%) | (50.17%) | (88.97%) | (2,788.74%) |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.35) | (96.73) | (111.69) | (544.67) | (381.34) | (210.55) | (98.20) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | — | 1.28 | 2.32 | 2.60 | 1.59 | 1.39 | 2.08 |
Average Assets |
— | 0.03 | 0.05 | 0.26 | 20.02 | 29.62 | 14.65 | 5.59 |
Average Common Equity |
— | (1.96) | (1.96) | (3.47) | 16.63 | 27.03 | 9.26 | 0.51 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates